Alzheimer’s research has a diversity problem. The disease disproportionately strikes underrepresented groups, including Black and Hispanic people, but clinical trials include mostly white participants — an issue Jackson publishes on and speaks about frequently. His long-standing efforts calling out the need to understand ethnic and racial differences in Alzheimer’s and other diseases are gaining traction with ever-growing audiences. In 2022, he lectured and published widely about justice in clinical research and health equity.
Industry
Location
-
Boston, MA
